



## **ITM Isotope Technologies Munich to Present at the 40th Annual J.P. Morgan Healthcare Conference**

**Garching / Munich, January 5, 2022** - [ITM Isotope Technologies Munich SE \(ITM\)](#), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster will present a corporate overview and update at the virtual 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 10.30am ET (4.30pm CET).

- End -

### **ITM Isotope Technologies Munich SE**

ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline, including two phase III studies, combining its high-quality radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better. For more information please visit: [www.itm-radiopharma.com](http://www.itm-radiopharma.com).

### **ITM Contact**

#### **Corporate Communications**

Julia Hofmann / Susanne Karlsson

Corporate Communications

Phone: +49 89 329 8986 1502

Email: [communications@itm-radiopharma.com](mailto:communications@itm-radiopharma.com)

#### **Investor Contact**

Ben Orzelek

Investor Relations

Phone: +49 89 329 8986 1009

Email: [Ben.Orzelek@itm-radiopharma.com](mailto:Ben.Orzelek@itm-radiopharma.com)

### **ITM Media Requests**

#### **Trophic Communications**

Trophic Communications

Stephanie May or Valeria Fisher

Phone: +49 175 8041816

Email: [itm@trophic.eu](mailto:itm@trophic.eu)